Synteract taps industry veterans Dilworth and Schrader to join its team

CRO Synteract hires industry veterans Lisa Dilworth and Elisabeth Schrader. (Pixabay)

Synteract, a CRO based in San Diego and North Carolina, has tapped industry veterans Lisa Dilworth and Elisabeth Schrader to join its team.

Dilworth will be vice president, rare and orphan disease, and Schrader comes on board as executive director, program strategy, pediatrics and rare diseases.

Prior to Synteract, Dilworth was director of therapeutics expertise, scientific affairs and rare disease at PRA Health Sciences and has had managerial roles at UCB and Chiltern International. Schrader comes to Synteract from Syneos where she was executive director, clinical development. Prior to Syneos, she was senior customer operations director at IQVIA where she supported clients with a rare disease and pediatric focus.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“With extensive and varied backgrounds in rare and orphan drug development, Lisa and Elisabeth are excellent additions to our development center,” Steve Powel, Synteract’s chief executive, said in a statement.

In July, Synteract acquired specialty contract researchers Cu-Tech, which is based in New Jersey, for an undisclosed price. The deal is part of Synteract’s move to establish a dedicated center for the development of dermatology products and establish itself as a destination for skin-care clinical trials. Over the past two decades, Cu-Tech has managed more than 130 dermatology trails covering a number of indications.


Suggested Articles

Novartis, Otsuka, Pfizer and Sanofi will use technology from Verily’s Project Baseline to carry out clinical studies in various disease areas.

Biotech-CRO hybrid Evotec is continuing its buying and collaborating strategy with its acquisition of U.S. biologics company Just Biotherapeutics.

Computing-enabled R&D shop Schrödinger will use its $110 million haul to advance its nascent pipeline of wholly owned drugs.